Sage Therapeutic Stock Performance
| SAGE Stock | USD 5.47 0.08 1.44% |
The entity has a beta of 2.02, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Sage Therapeutic will likely underperform. At this point, Sage Therapeutic has a negative expected return of -0.46%. Please make sure to validate Sage Therapeutic's treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Sage Therapeutic performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sage Therapeutic has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return (1.44) | Five Day Return (5.36) | Year To Date Return (75.67) | Ten Year Return (86.12) | All Time Return (81.83) |
1 | Sage Therapeutics, Inc. Sued for Securities Law Violations Investors Should Contact Levi Korsinsky for More Information SAGE | 10/16/2024 |
2 | Class Action Filed Against Sage Therapeutics, Inc. Seeking Recovery for Investors - Contact Levi Korsinsky | 10/21/2024 |
3 | The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. | 10/25/2024 |
4 | Sage and Artis Trade Join Forces to Accelerate Document Automation and Drive Efficiency in Secured Finance | 10/31/2024 |
5 | Sage Therapeutics Price Target Cut to 8.00 by Analysts at Oppenheimer | 11/01/2024 |
6 | Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer Head of Quality | 11/06/2024 |
7 | SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japans Patent Office Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinan... | 11/14/2024 |
8 | Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor in the Treatment of Cognitive Impairment Associated with Huntingtons... | 11/20/2024 |
9 | Sage raised to sector perform by RBC in wake of drug failure | 11/21/2024 |
10 | A Brand New Bathhouse is Open in Renton | 11/26/2024 |
| Begin Period Cash Flow | 164 M |
Sage |
Sage Therapeutic Relative Risk vs. Return Landscape
If you would invest 791.00 in Sage Therapeutic on September 3, 2024 and sell it today you would lose (244.00) from holding Sage Therapeutic or give up 30.85% of portfolio value over 90 days. Sage Therapeutic is currently does not generate positive expected returns and assumes 4.6783% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Sage, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sage Therapeutic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sage Therapeutic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sage Therapeutic, and traders can use it to determine the average amount a Sage Therapeutic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.098
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SAGE |
Estimated Market Risk
| 4.68 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.46 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sage Therapeutic is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sage Therapeutic by adding Sage Therapeutic to a well-diversified portfolio.
Sage Therapeutic Fundamentals Growth
Sage Stock prices reflect investors' perceptions of the future prospects and financial health of Sage Therapeutic, and Sage Therapeutic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sage Stock performance.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.3 | ||||
| Operating Margin | (8.53) % | ||||
| Current Valuation | (224.26 M) | ||||
| Shares Outstanding | 61.17 M | ||||
| Price To Earning | 3.07 X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 3.19 X | ||||
| Revenue | 86.45 M | ||||
| Gross Profit | (319.29 M) | ||||
| EBITDA | (545.07 M) | ||||
| Net Income | (541.49 M) | ||||
| Cash And Equivalents | 1.51 B | ||||
| Cash Per Share | 25.47 X | ||||
| Total Debt | 5.17 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 17.69 X | ||||
| Book Value Per Share | 9.02 X | ||||
| Cash Flow From Operations | (540.59 M) | ||||
| Earnings Per Share | (5.57) X | ||||
| Market Capitalization | 339.51 M | ||||
| Total Asset | 882.28 M | ||||
| Retained Earnings | (2.57 B) | ||||
| Working Capital | 786.6 M | ||||
| Current Asset | 188.49 M | ||||
| Current Liabilities | 15.31 M | ||||
About Sage Therapeutic Performance
By analyzing Sage Therapeutic's fundamental ratios, stakeholders can gain valuable insights into Sage Therapeutic's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Sage Therapeutic has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Sage Therapeutic has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 253.59 | 266.27 | |
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.73) | (0.76) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.68) | (0.64) |
Things to note about Sage Therapeutic performance evaluation
Checking the ongoing alerts about Sage Therapeutic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sage Therapeutic help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sage Therapeutic generated a negative expected return over the last 90 days | |
| Sage Therapeutic has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 86.45 M. Net Loss for the year was (541.49 M) with loss before overhead, payroll, taxes, and interest of (319.29 M). | |
| Sage Therapeutic currently holds about 1.51 B in cash with (540.59 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 25.47, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Over 86.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: A Brand New Bathhouse is Open in Renton |
- Analyzing Sage Therapeutic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sage Therapeutic's stock is overvalued or undervalued compared to its peers.
- Examining Sage Therapeutic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sage Therapeutic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sage Therapeutic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sage Therapeutic's stock. These opinions can provide insight into Sage Therapeutic's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Stocks Directory Find actively traded stocks across global markets |